A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization.
Preventing ligand-dependent ErbB2 receptor heterodimers by an anti-ErbB2 monoclonal antibody shuts down receptor signaling and has potent antitumor activity even in tumors that express low levels of ErbB2, a finding that could result in a larger number of patients benefiting from anti-ErbB2 therapies.
Vall d'Hebron University Hospital and Universidad Autonoma de Barcelona, 08035 Barcelona, Spain. basegla@hg.vhebron.es
Jose
J
Baselga
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D019281:Dimerization; D006801:Humans; D008024:Ligands; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
D000911:Antibodies, Monoclonal; D008024:Ligands; D018719:Erb-b2 Receptor Tyrosine Kinases